View This Page in PDF

puppypompAI and Robotics

Nov 14, 2013 (3 years and 1 month ago)

80 views

Corporate Headquarters
389 Nichol Mill Lane
Franklin,Tennessee 37067
(615) 844-1280
www.biomimetics.com
Annual Meeting
The annual meeting of stockholders will be held on
Thursday,June 12,2008,at 8:00 a.m.CDT at the
Company’s headquarters.
Transfer Agent & Registrar
American Stock Transfer & Trust Company
59 Maiden Lane
New York,NY 10038
(800) 937-5449
www.amstock.com
Independent Registered Public Accountants
Ernst & Young LLP
Nashville,Tennessee
Legal Counsel
Morrison & Foerster LLP
New York,New York
Harwell Howard Hyne Gabbert & Manner,P.C.
Nashville,Tennessee
Form 10-K/Investor Contact
A copy of the Company’s Annual Report on Form
10-K,filed with the Securities and Exchange
Commission,may be obtained from the Company at
no charge or can be accessed on our website or at
www
.sec
.go
v
.
R
equests for the Annual Report on
Form 10-K and other investor information should be
dir
ected to Kearstin Patterson,Associate Director of
C
or
p
orate Communications,at the Company’s
corporate office,at www.biomimetics.com or by
email to:info@biomimetics.com.
Stock Listing
The Company’s common stock is traded on the
NASDAQ Global Market under the symbol BMTI.
Cautionary Note Regarding
Forward-Looking Statements
This report contains “forward-looking statements”
within the meaning of the Private Securities
Litigation Reform Act of 1995.These forward-looking
statements are based on the current intent and
expectations of the management of BioMimetic.
These statements are not guarantees of future
performance and involve risks and uncertainties that
are difficult to predict.There are many important
factors that could cause actual results to differ
materially from those indicated in the forward-
looking statements.BioMimetic's actual results and
the timing and outcome of events may differ
materially from those expressed in or implied by the
forward-looking statements because of risks
associated with the marketing of BioMimetic's
product and product candidates,unproven
preclinical and clinical development activities,
regulatory oversight,and other risks detailed in the
Company's filings with the Securities and Exchange
Commission.Except as required by law,BioMimetic
undertakes no responsibility for updating the
information contained in this report beyond the
published date,whether as a result of new
information,future events or otherwise.